Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study

American Journal of Clinical Nutrition

Volumn 101, Issue 1, 2015, Pages 126-134

  Jiao, Li ^a   Stolzenberg Solomon, Rachael ^b   Zimmerman, Thea Palmer ^c   Duan, Zhigang ^a   Chen, Liang ^a   Kahle, Lisa ^d   Risch, Adam ^d   Subar, Amy F ^b   Cross, Amanda J ^e   Hollenbeck, Albert ^g   Vlassara, Helen ^f   Striker, Gary ^f   Sinha, Rashmi ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WESTAT   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g AARP   (United States)

Author keywords

Advanced glycation end products; Diet; Inflammation; Pancreatic cancer; Risk

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LYSINE DERIVATIVE; N EPSILON (CARBOXYMETHYL)LYSINE; UNCLASSIFIED DRUG; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; DIETARY INTAKE; FEMALE; FOLLOW UP; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PROCESSED MEAT; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RED MEAT; WHITE MEAT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANALYSIS; COHORT ANALYSIS; DIET; FACTUAL DATABASE; MEAT; MIDDLE AGED; NORMAL DISTRIBUTION; PANCREATIC NEOPLASMS; QUESTIONNAIRE; RISK; SEX DIFFERENCE; UNITED STATES;

AGED; COHORT STUDIES; DATABASES, FACTUAL; DIET; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MEAT; MIDDLE AGED; NORMAL DISTRIBUTION; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SEX FACTORS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84919664382     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.114.098061     Document Type: Article

References (50)

1. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, DC: AICR;2007.
2. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-94.
3. Vistoli G, De MD, Cipak A, Zarkovic N, Carini M, Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013; 47(Suppl 1):3-27.
4. Hull GL, Woodside JV, Ames JM, Cuskelly GLN. N-(carboxymethyl) lysine content of foods commonly consumed in a Western style diet. Food Chem 2012;131:170-4.
5. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110:911-6.
6. Song F, Schmidt AM. Glycation and insulin resistance: novel mechanisms and unique targets? Arterioscler Thromb Vasc Biol 2012;32:1760-5.
7. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008;14:987-9.
8. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461-6.
9. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-6.
10. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-26.
11. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
12. Henle T. Dietary advanced glycation end products-a risk to human health? A call for an interdisciplinary debate. Mol Nutr Food Res 2007; 51:1075-8.
13. Sebeková K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects-PRO. Mol Nutr Food Res 2007;51: 1079-84.
14. Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, Stolzenberg-Solomon RZ. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res 2011;71: 3582-9.
15. Stolzenberg-Solomon RZ, Cross AJ, Silverman DT, Schairer C, Thompson FE, Kipnis V, Subar AF, Hollenbeck A, Schatzkin A, Sinha R. Meat and meat-mutagen intake and pancreatic cancer risk in the NIH-AARP cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2664-75.
16. Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt S, McIntosh A, Rosenfeld S. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol 2001;154:1089-99.
17. USDA Food and nutrient database for dietary studies, 3.0. Beltsville (MD): Agricultural Research Service, Food Surveys Research Group; 2008.
18. Subar AF, Midthune D, Kulldorff M, Brown CC, Thompson FE, Kipnis V, Schatzkin A. Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. Am J Epidemiol 2000;152:279-86.
19. Sinha R, Cross A, Curtin J, Zimmerman T, McNutt S, Risch A, Holden J. Development of a food frequency questionnaire module and databases for compounds in cooked and processed meats. Mol Nutr Food Res 2005;49:648-55.
20. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-91.
21. Founds HW, Sadeghi H, inventors. Alteon Inc., assignee. Monoclonal antibodies specific for advanced glycoxylation endproducts in biological samples. United States patent US5892000. 1995 Dec 29.
22. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, Stahl P. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004;47:1376-9.
23. Flood A, Subar AF, Hull SG, Zimmerman TP, Jenkins DJ, Schatzkin A. Methodology for adding glycemic load values to the National Cancer Institute Diet History Questionnaire database. J Am Diet Assoc 2006; 106:393-402.
24. Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012;106:603-7.
25. Thornalley PJ. Advanced glycation end products in renal failure. J Ren Nutr 2006;16:178-84.
26. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stressinducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002;8:337-46.
27. Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, Vlassara H. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 2007;170:1893-902.
28. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, Vlassara H. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 2008;173: 327-36.
29. Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, Forbes JM, Angus PW. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol 2014;60:832-8.
30. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011;7:526-39.
31. West RK, Moshier E, Lubitz I, Schmeidler J, Godbold J, Cai W, Uribarri J, Vlassara H, Silverman JM, Beeri MS. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev 2014;140:10-2.
32. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005;15:16R-28R.
33. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427-33.
34. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 2012;109:15888-93.
35. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996;222:700-5.
36. Monnier VM, Sell DR. Prevention and repair of protein damage by the Maillard reaction in vivo. Rejuvenation Res 2006;9:264-73.
37. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, Chen D. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012;221:387-96.
38. Francis-Sedlak ME, Moya ML, Huang JJ, Lucas SA, Chandrasekharan N, Larson JC, Cheng MH, Brey EM. Collagen glycation alters neovascularization in vitro and in vivo. Microvasc Res 2010;80:3-9.
39. Abe H, Matsubara T, Iehara N, Nagai K, Takahashi T, Arai H, Kita T, Doi T. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004;279:14201-6.
40. Jägerstad M, Skog K. Genotoxicity of heat-processed foods. Mutat Res 2005;574:156-72.
41. Peng X, Ma J, Chen F, Wang M. Naturally occurring inhibitors against the formation of advanced glycation end-products. Food Funct 2011;2:289-301.
42. Desai K, Wu L. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Recent Pat Cardiovasc Drug Discov 2007;2:89-99.
43. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999;58:1765-73.
44. Cai W, Uribarri J, Zhu L, Chen X, Swamy S, Zhao Z, Grosjean F, Simonaro C, Kuchel GA, Schnaider-Beeri M, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA 2014;111:4940-5.
45. Gaens KH, Goossens GH, Niessen PM, van Greevenbroek MM, van der Kallen CJ, Niessen HW, Rensen SS, Buurman WA, Greve JW, Blaak EE, et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol 2014;34:1199-208.
46. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007;30:2579-82.
47. Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, Holst JJ, Nielsen J, de Courten B, Dragsted LO, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014;37:88-95.
48. Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bügel S, Nielsen J, Skibsted LH, Dragsted LO. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 2013;60:10-37.
49. Ames JM. Determination of N epsilon-(carboxymethyl)lysine in foods and related systems. Ann N Y Acad Sci 2008;1126:20-4.
50. Nguyen HT, Van der Fels-Klerx HJ, Van Boekel MAJS. N-(carboxymethyl)lysine: a review on analytical methods, formation, and occurrence in processed food, and health impact. Food Rev Int 2013;30:36-52.